Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

BACKGROUND: Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the management of hematologic toxicities. A previous pooled analysis from the PALOMA clinic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res
Hlavní autoři: Ettl, Johannes, Im, Seock-Ah, Ro, Jungsil, Masuda, Norikazu, Colleoni, Marco, Schnell, Patrick, Bananis, Eustratios, Lu, Dongrui R., Cristofanilli, Massimo, Rugo, Hope S., Finn, Richard S.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7068918/
https://ncbi.nlm.nih.gov/pubmed/32164785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01263-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky